TaiMed Biologics

4147 · TPEx

Public Market Listing

4147TPEx

TPEx primary exchange listing

Live quotes, historical charts, and market capitalization for TaiMed Biologics are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(2 total)
2Total Assets
1Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 2 of 2 assets
Target & Modality
Ibalizumab(Trogarzo)
Approved
CD4 receptorMonoclonal antibody
HIV
Phase 2
CD4; HIV envelopeCombination
HIV

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
May 2027 (1)
TMB-365 / TMB-380Phase 2HIV -1 Infection
Est. primary completion 2027-05 · NCT07215468 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Annual history (2 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$20M——$5.4Mreport ↗
View 1 more year
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-9M———$2.5Mreport ↗